Lung function – Page 2 – Communicable Diseases Research

Clinical predictors of lung function in patients recovering from mild COVID-19

Observational Study

Published on 2022-07-312022-10-05
Journal: BMC Pulmonary Medicine
[Category] 임상,

Multiplex protein profiling of bronchial aspirates reveals disease-, mortality- and respiratory sequelae-associated signatures in critically ill patients with ARDS secondary to SARS-CoV-2 infection

기관지 흡인물의 다중 단백질 프로파일링은 SARS-CoV-2 감염에 이차적으로 ARDS가 있는 중환자에서 질병, 사망률 및 호흡기 후유증과 관련된 징후를 나타냅니다.

Multicenter Study

Published on 2022-07-292022-09-11
Journal: Frontiers in Immunology
[Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료기술,

[키워드] acute respiratory distress acute respiratory distress syndrome adverse outcomes AGR2 all-cause mortality ARDS association BAS bronchial bronchial aspirate confounding factors correlated COVID-19 COVID-19 patients Cox regression model Cox regression models Critically ill Critically ill patient critically ill patients CST5 Decision making determinant disease pathogenesis DPP7 ENTPD2 expressed Factor FCRL1 highest hospital discharge host response ICU ICU – intensive care unit identify IL-1α immune IMV intensive care Invasive mechanical ventilation Kaplan-Meier curve Kaplan-Meier curves KYAT1 lung cells Lung function mechanism molecular Mortality mortality risk multicenter study NADK Non-COVID-19 Non-COVID-19 patients nonsurvivor nonsurvivors NQO2 NTF4 OSM outcomes Pathogenesis pathology Poor Protein proteomic proteomics proteomics. proximity extension assay PTN quantified radiological feature radiological features random Random forest reduced respiratory respiratory distress Respiratory distress syndrome reveal risk Risk assessment SARS-COV-2 infection SRPK2 subgroup subgroups supported Survivors the disease the strongest THOP1 TRAIL TSS TYMP Viral viral infectivity were used with COVID-19
[DOI] 10.3389/fimmu.2022.942443 PMC 바로가기 [Article Type] Multicenter Study

Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung disease

Clinical Trial

Published on 2022-07-232022-10-05
Journal: Orphanet Journal of Rare Diseases
[Category] COVID19(2023년), SARS, 임상,

[키워드] absence adverse event age all subject approval ARMS calculated chILD. childhood children Controlled trial double-blind effect size Endpoint evaluated four subject groups HCQ Health Hydroxychloroquine identify Interstitial lung disease Interstitial lung diseases lack lung Lung function multicentre Munich not differ not different offered outcome Oxygenation participated phase 2 trial Placebo placebo-controlled primary endpoint Pulmonary function Quality of life Randomized randomized-controlled trial Registered Registration respiratory rate Respiratory Support secondary study population subject Treatment treatment effects treatment period Trial university were given Withdrawal
[DOI] 10.1186/s13023-022-02399-2 PMC 바로가기 [Article Type] Clinical Trial

Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease

Research

Published on 2022-07-192022-10-05
Journal: Scientific Reports
[Category] 바이오마커, 치료제,

Effect of Pulmonary Rehabilitation Approaches on Dyspnea, Exercise Capacity, Fatigue, Lung Functions, and Quality of Life in Patients With COVID-19: A Systematic Review and Meta-analysis

Review article

Published on 2022-07-012022-10-05
Journal: Archives of physical medicine and rehabilitation
[Category] 임상,

[키워드] 6-minute walk test 6MWT6-minute walk test 95% CI acute COVID-19 appear Capacity chronic obstructive pulmonary disease Controlled trial COPDchronic obstructive pulmonary disease COVID-19 COVID-19 patients database Dyspnea Effect effective evaluate the effect evaluated exercise Exercise capacity extraction fatigue feasible forced vital capacity functions FVCForced vital capacity independent indicate Intervention life lung Lung function mean difference Mild mild symptoms objective outcome outcome measure participant Patient patients with COVID-19 PRpulmonary rehabilitation pulmonary pulmonary rehabilitation QoLquality of life Quality Quality of life random effect Randomized controlled trial RCT RCTrandomized controlled trial RCTs review risk of bia Safe searched Selection severe symptoms SFShort-Form Health Survey SGRQSt. George's Respiratory Questionnaire Short-Form Health Survey significantly SMD Source St. George's Respiratory Questionnaire synthesis ventilatory Web of Science
[DOI] 10.1016/j.apmr.2022.06.007 [Article Type] Review article

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study

Observational Study

Published on 2022-07-012022-10-05
Journal: BMJ Open Respiratory Research
[Category] COVID19(2023년), SARS, 임상,

[키워드] analysed approval baseline data Care Characteristics Clinical course clinical phenotype Comorbidities Control COVID-19 COVID-19 pandemic determine Ethics event Factor Features follow-up period General population group higher risk Host illness Impact include Infection Infectious disease Interstitial Fibrosis Interstitial lung disease intervals Local Lung function measure Non-COVID-19 non-infected outcome outcomes Patient patients Prospective Study pulmonary sarcoidosis Quality of life rationale recorded recruitment required respiratory respiratory infections respiratory pathogen respiratory viral sarcoidosis SARS-CoV-2 severity study cohort survival trajectory USA Viral infection.
[DOI] 10.1136/bmjresp-2022-001254 PMC 바로가기 [Article Type] Observational Study

A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): a randomised controlled trial

Randomized Controlled Trial

Published on 2022-07-012022-10-05
Journal: Thorax
[Category] 임상,

COVID-19: Omicron – the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2

COVID-19: 오미크론 - 최신, 가장 덜 독성이지만 SARS-CoV-2의 우려의 마지막 변종은 아닐 것입니다.

Review

Published on 2022-07-012022-09-11
Journal: Microbial Biotechnology
[Category] COVID19(2023년), SARS, 변종,

[키워드] affected Antibody Response Antiviral booster breadth cell entry Cellular immune response convalescent patient Convalescent patients COVID-19 pandemic Delta demonstrated dominant Endocytic pathway experiment explain fusion hamsters Immune escape immunization Infection intrinsic less Lineage Lung function mainstream mice monoclonal antibodies mutated Mutation neutralization omicron Omicron variant plasma membrane population immunity preserved question raising Replication respiratory tract SARS-CoV-2 SARS-CoV-2 strain serum antibodies serum antibody Severe infection severe infections South Africa Spike protein the spike protein therapeutic titre trajectory Transmission vaccinee vaccinees variant virulence virulent VoC widespread
[DOI] 10.1111/1751-7915.14064 PMC 바로가기 [Article Type] Review

Dnah9 mutant mice and organoid models recapitulate the clinical features of patients with PCD and provide an excellent platform for drug screening

Research

Published on 2022-06-212022-10-05
Journal: Cell Death & Disease
[Category] 변종,

Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP)

만성 폐 질환 환자에 초점을 맞춘 SARS-CoV-2 감염 환자 관리(2022년 1월 10일 기준) : 오스트리아 폐렴 학회(ASP)의 업데이트된 성명

Article

Published on 2022-05-012022-09-11
Journal: Wiener Klinische Wochenschrift
[Category] Coronavirus, COVID19(2023년), SARS, 변종,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition addressed Adults affected ASP association breakdown bronchoscopy Care cause children chronic chronic lung disease chronic lung diseases concerning coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 disease delta variant died disease effective elevated expected Health health system Immune modulators increased risk Infection lockdown Long Long COVID lung Lung disease Lung function measure Mechanical mechanical ventilation Most patients Omicron variant Patient patients patients with SARS-CoV-2 Pediatric lung disease. Pneumology predominant Prevent professional provided reaction rising risk risk of death SARS-CoV-2 SARS-CoV‑2 SARS-CoV‑2 infection severe acute respiratory syndrome Coronavirus severe COVID-19 disease social distancing Society Spread therapy vaccination vaccination rate Vaccinations variant
[DOI] 10.1007/s00508-022-02018-x PMC 바로가기 [Article Type] Article